CareDx, Inc (NASDAQ:CDNA) Shares Sold by Deutsche Bank AG

Deutsche Bank AG trimmed its stake in shares of CareDx, Inc (NASDAQ:CDNA - Free Report) by 15.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 126,692 shares of the company's stock after selling 23,401 shares during the period. Deutsche Bank AG owned 0.24% of CareDx worth $2,712,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Divisadero Street Capital Management LP acquired a new stake in CareDx in the 4th quarter worth about $15,239,000. Bamco Inc. NY increased its position in shares of CareDx by 17.6% during the fourth quarter. Bamco Inc. NY now owns 2,207,299 shares of the company's stock worth $47,258,000 after purchasing an additional 330,627 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of CareDx by 29.8% during the fourth quarter. BNP Paribas Financial Markets now owns 64,141 shares of the company's stock worth $1,373,000 after purchasing an additional 14,721 shares in the last quarter. Ameriprise Financial Inc. increased its position in shares of CareDx by 15.8% during the fourth quarter. Ameriprise Financial Inc. now owns 279,309 shares of the company's stock worth $5,980,000 after purchasing an additional 38,101 shares in the last quarter. Finally, Algert Global LLC increased its position in shares of CareDx by 26.1% during the fourth quarter. Algert Global LLC now owns 36,040 shares of the company's stock worth $772,000 after purchasing an additional 7,460 shares in the last quarter.

Analyst Ratings Changes

A number of equities research analysts have recently commented on the stock. Stephens reiterated an "overweight" rating and issued a $40.00 target price on shares of CareDx in a research report on Monday, May 5th. Wall Street Zen cut shares of CareDx from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. The Goldman Sachs Group decreased their target price on shares of CareDx from $34.00 to $26.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Finally, HC Wainwright reissued a "neutral" rating and issued a $25.00 target price on shares of CareDx in a research note on Monday, May 5th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $30.33.

Insider Buying and Selling at CareDx

In other news, Director Peter Maag sold 13,281 shares of CareDx stock in a transaction on Wednesday, April 30th. The stock was sold at an average price of $17.23, for a total value of $228,831.63. Following the completion of the sale, the director now directly owns 316,743 shares of the company's stock, valued at approximately $5,457,481.89. The trade was a 4.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Christine Cournoyer sold 29,136 shares of CareDx stock in a transaction on Monday, May 12th. The shares were sold at an average price of $15.96, for a total value of $465,010.56. Following the completion of the sale, the director now directly owns 37,045 shares of the company's stock, valued at $591,238.20. The trade was a 44.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,382 shares of company stock valued at $934,509 over the last 90 days. 4.90% of the stock is owned by insiders.

CareDx Stock Performance

Shares of NASDAQ CDNA traded down $0.16 during midday trading on Friday, reaching $16.95. 982,264 shares of the stock were exchanged, compared to its average volume of 894,949. The company has a 50 day simple moving average of $17.48 and a 200 day simple moving average of $20.73. The stock has a market capitalization of $943.79 million, a P/E ratio of -6.28 and a beta of 2.27. CareDx, Inc has a twelve month low of $12.90 and a twelve month high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last posted its earnings results on Wednesday, April 30th. The company reported $0.09 EPS for the quarter, beating analysts' consensus estimates of $0.06 by $0.03. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The company had revenue of $84.69 million for the quarter, compared to the consensus estimate of $84.56 million. During the same quarter in the previous year, the business earned ($0.03) earnings per share. The company's revenue for the quarter was up 17.6% on a year-over-year basis. On average, research analysts expect that CareDx, Inc will post -0.9 earnings per share for the current year.

CareDx Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.